Branden M Roberts, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1301 W Main St, Lake City, IA 51449 Phone: 712-464-3171 Fax: 712-464-3269 |
News Archive
Sanford Project researchers have reached a critical milestone in a clinical trial testing a combination of two medications to determine if the drugs can help patients with type 1 diabetes (T1D) keep their blood glucose levels under control with less or no insulin. The full number of patients needed to complete this first trial, termed Restore Pancreatic Insulin Response in type 1 diabetes (REPAIR-T1D), has been reached.
Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
A patent application for a drug that could destroy the deadly childhood disease known as acute lymphoblastic leukemia — and potentially other cancers as well — has been submitted by researchers at Sandia National Laboratories, the University of Maryland and the MD Anderson Cancer Center in Houston.
Viruses are tiny bundles of DNA or RNA which have the ability to infect host cells, hijack the machinery of the host cell and then replicate. Once the host cell's resources are exhausted, the viral particles are released to infect other cells. In this way, the viruses ensure their survival, often at the expense of the host.
How can caregivers recognize the difference between normal age-related memory lapses and memory loss related to dementia? Prestige Assisted Living at Sierra Vista will host an educational speaker series that offers insight into memory care issues, beginning in March.
› Verified 4 days ago